Phase III Trial Binimetinib Increases PFS in NRAS-Mutant Melanoma vs. Dacarbazine

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Array BioPharma reported top-line results from the ongoing phase III clinical trial of binimetinib in patients with advanced NRAS-mutant melanoma, demonstrating that the study met its primary endpoint of improving progression-free survival when compared with dacarbazine treatment.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe

YOU MAY BE INTERESTED IN

Physician-scientists by day, a funk-loving musical troupe by night. You may have seen The CheckPoints—a 13 member cover band with a three-piece brass section and Jim Allison on harmonica—movin’, groovin’, and gettin’ down as a mainstay closing act at ASCO, AACR, or the Society for Immunotherapy of Cancer annual meetings.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login